elezanumab: Clinical Trials

7 trials of elezanumab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 1 no longer available, 1 terminated. 4 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 24Completed 4
Phase 12Completed 1, Terminated 1

Follow elezanumab: new trials by email Literature Review of elezanumab trials Research Report on elezanumab

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke
Elezanumab, Placebo - Acute Ischemic Stroke
Phase 2CompletedAbbVie1212020-11-092025-12-22
Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI)
Elezanumab, Placebo - Spinal Cord Injury (SCI)
Phase 2CompletedAbbVie602020-09-062026-02-11
A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis
elezanumab, placebo - Multiple Sclerosis (MS)
Phase 2CompletedAbbVie1232019-02-272023-12-21
A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis
elezanumab, placebo - Multiple Sclerosis (MS)
Phase 2CompletedAbbVie2082018-12-112023-12-22
A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis
ABT-555, Placebo - Multiple Sclerosis
Phase 1CompletedAbbVie202016-10-182018-05-17
[11C]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT 555 in Subjects With Relapsing Forms of Multiple Sclerosis
ABT-555 - Multiple Sclerosis
Phase 1TerminatedAbbVie42015-10-012017-02-08
Expanded Access to Elezanumab
Elezanumab - Acute Spinal Cord Injury (SCI)
No longer availableAbbVie2026-05-22

Conditions studied

Multiple Sclerosis (4)  ·  Ischemic Stroke (1)  ·  Multiple Sclerosis, Chronic Progressive (1)  ·  Spinal Cord Injuries (1)

Sponsors

AbbVie (7)

Countries

United States (5)  ·  Canada (4)  ·  Australia (2)  ·  Japan (2)  ·  South Korea (2)  ·  Spain (2)  ·  Israel (1)  ·  United Kingdom (1)

Top investigators

Steven Greenberg, MD (1)

NIH funding

2019 (2), 2015 (1)